New study sheds light on angiogenesis inhibitors.
McBride
Deborah
D
Kaiser Permanente Oakland Medical Center, CA USA.
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068258:Bevacizumab; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D051379:Mice; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000068258:Bevacizumab; D000077210:Sunitinib